SCHEMBL2992998

SCHEMBL2992998

CON(C)C(=O)C1CC2CN(C(=O)OC(C)(C)C)CC2C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.55
JAK1 P23458 2/20 0.44
JAK2 O60674 1/20 0.44
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
HPGD P15428 1/20 0.38
HSD11B1 P28845 1/20 0.37
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RECQL P46063 1/20 0.36
USP30 Q70CQ3 4/20 0.36
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
EPHX2 P34913 1/20 0.35
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23230817 1.00 NR1H2 (0.55) NR1H2JAK1JAK2DDB1CRBN
SCHEMBL29745515 1.00 NR1H2 (0.55) NR1H2JAK1JAK2DDB1CRBN
SCHEMBL278133 0.88 NR1H2 (0.45) NR1H2DDB1CRBNMEN1ALDH1A1
SCHEMBL2990494 0.87 NR1H2 (0.43) NR1H2JAK1JAK2DDB1CRBN
SCHEMBL23214845 0.86 NR1H2 (0.51) NR1H2JAK1JAK2DDB1CRBN
SCHEMBL17913807 0.83 NR1H2 (0.43) NR1H2JAK1JAK2DDB1CRBN
SCHEMBL18485336 0.83 NR1H2 (0.43) NR1H2JAK1JAK2DDB1CRBN
SCHEMBL586312 0.83 HPGD (0.54) JAK1JAK2MEN1ALDH1A1MAPT
SCHEMBL23215563 0.83 NR1H2 (0.48) NR1H2JAK1JAK2DDB1CRBN
SCHEMBL389962 0.83 HPGD (0.54) JAK1JAK2MEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198296-B2 Sub-type selective azabicycloalkane derivatives TARGACEPT, INC. (US) 2012-06-12 US disclosed
US-20100173968-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES TARGACEPT, INC. (US) 2010-07-08 US disclosed
EP-2139857-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES Targacept Inc. (US) 2010-01-06 EP disclosed
WO-2008121686-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES TARGACEPT, INC. (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173968-A1 SUB-TYPE SELECTIVE AZABICYCLOALKANE DERIVATIVES CHRNB2, CHRNB4, CHRNA4 NR1H2 583/4885JAK1 2537/4885JAK2 3711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.